Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

Study identifier:D9612L00080

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects on Days 1 and 5 of Intravenous Treatment

Medical condition

Healthy

Phase

Phase 4

Healthy volunteers

Yes

Study drug

Nexium, Prevacid

Sex

All

Actual Enrollment

100

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Sept 2005

Primary Completion Date: -

Study Completion Date: 01 Feb 2006

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=662&filename=CSR-D9612L00080.pdf
Download
CSR-D9612L00080.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Information Center

800-236-9933, (US - 8a-7p EST)

Contact Backup

If outside the U.S.:

001-800-236-9933

Investigators

Principal Investigator

Nexium Medical Science Director

AstraZeneca